Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investigation Of FDA Employee Misconduct Charges Returns to OIG

This article was originally published in The Tan Sheet

Executive Summary

A "stronger appearance of impartiality, integrity" will result from returning investigative authority over allegations of FDA employee misconduct to the Department of Health and Human Services Office of Inspector General, a House Energy and Commerce Committee aide says

You may also be interested in...



Energy & Commerce Committee Inquires Into FDA Contracting Conflicts

The new Democratic-controlled House Energy and Commerce Committee initiated its first public inquiry into FDA Jan. 22, seeking documents relating to the oversight of conflicts of interest in the agency's contracting practices

FDA retaliation would be investigated by outside group under FDA reform bill -- Rep. Barton.

FDA RETALIATION INVESTIGATIONS UNDER "INDEPENDENT" OUTSIDE PROCESS will be included in House legislation aimed at reforming FDA, House Commerce/oversight subcommittee Chairman Joe Barton (R-Tex.) promised in his opening statement during a Nov. 15 subcommittee hearing. "As this Congress moves forward on FDA reform...I will insist on an independent review process outside of FDA to handle cases" of alleged retaliation by the agency against industry, Barton said.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Topics

UsernamePublicRestriction

Register

PS101134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel